CAPOX

In this article, we will explore the different aspects related to CAPOX and its impact on contemporary society. From its beginnings to the present, CAPOX has played a crucial role in various areas, influencing the way we perceive the world around us. Throughout these pages, we will analyze its evolution, its multiple facets and its relevance in the current context. Through interviews with experts, recent research and concrete examples, we will delve into the universe of CAPOX to understand its importance and its possible implications in the future.

Pre- and post-chemotherapy images of a T3 N1 M0 cStage IIIa colorectal cancer. Four courses of CAPOX therapy.

CAPOX (also called XELOX[1]) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.[2][3]

Xelox regime operates in 3-week cycles, usually with 8 cycles in total; Xeloda is taken orally twice daily for two weeks, while oxaliplatin is administered by IV on the first day of the cycle; there is a one-week rest period before the next cycle.

Adverse effects

References

  1. ^ Cassidy, J.; Tabernero, J.; Twelves, C.; Brunet, R.; Butts, C.; Conroy, T.; Debraud, F.; Figer, A.; Grossmann, J.; Sawada, N.; Schöffski, P.; Sobrero, A.; Van Cutsem, E.; Díaz-Rubio, E. (2004). "XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients with Metastatic Colorectal Cancer". Journal of Clinical Oncology. 22 (11): 2084–2091. doi:10.1200/JCO.2004.11.069. PMID 15169795.
  2. ^ Capecitabine Combined with Oxaliplatin (CapOx) in Clinical Practice: How Significant is Peripheral Neuropathy? D. J. Storey; M. Sakala; C. M. McLean; H. A. Phillips; L. K. Dawson; L. R. Wall; M. T. Fallon; S. Clive. Posted: 09/28/2010; Annals of Oncology. 2010;21(8):1657-1661. © 2010 Oxford University Press
  3. ^ Twelves C, Wong A, Nowacki MP, et al. (June 2005). "Capecitabine as adjuvant treatment for stage III colon cancer". N. Engl. J. Med. 352 (26): 2696–704. doi:10.1056/NEJMoa043116. PMID 15987918.